NCT02689167Unknown2 期
Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 226
- 试验地点
- 1
- 主要终点
- MDT (median duration of treatment)
研究概览
简要总结
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the consultation as part of their usual care. The patients will be included before Sunitinib treatment is started. Thereafter, sunitinib is initiated 50 mg/day; regimen 4/6 (Marketing Authorisation Indication), 4 weeks "on " alternating with 2 weeks "off "
As soon as a dose or schedule adjustment is required, regardless of cause, the patient will be randomised 1/1:
- Either into arm A and will receive 37.5mg of Sunitinib per day by the 4/6 regimen (in accordance with the Marketing Authorisation); 4 weeks "on " alternating with 2 weeks "off "
- Or into arm B and will receive 50mg of Sunitinib per day by the 2/3 regimen (investigational arm); 2 weeks "on " alternating with 1 week "off "
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women over 18 years old
- •Patients with local, advanced or inoperable or metastatic (MRCC) renal cell carcinoma who are starting first line treatment with Sunitinib 50mg (4/6 regimen) according to the Marketing Authorisation Indication
- •Patients with histologically or cytologically confirmed renal cancer, clear cell variant or with a clear cell component
- •Karnofsky performance status ≥ 70%
- •Adequate organ function:
- •Absolute neutrophil (N) count ≥ 1 500 / µL
- •Platelets ≥ 100 000 / µL
- •Haemoglobin ≥ 10 g/dL
- •Adjusted serum calcium ≤ 2.6 mmol/L
- •Creatinine clearance ≥ 30 mL/min (by the MDRD formula)
- •Total bilirubin ≤ 1.5 x ULN (upper limit of the normal range)
- •AST ≤ 2.5 x ULN and ALT ≤ 2.5 x ULN OR AST and ALT ≤ 5 x ULN if liver abnormalities due to liver metastases AST = aspartate aminotransferase ALT = alanine aminotransferase
排除标准
- •Renal carcinoma with no clear cell component.
- •Previous systemic treatment for the RCC regardless of type (including targeted therapy, immunotherapy, chemotherapy, hormone or experimental therapy). Previous or concomitant treatment with a bisphosphonate or denosumab is allowed.
- •Patients whose clinical state and comorbidities are not consistent with administration of Sunitinib at the initial dose of 50mg/day 4 weeks out of
- •Grade 3 haemorrhage within 4 weeks before starting treatment with Sunitinib (according to the NCI-CTCAE toxicity score version 3.0).
- •The presence of a past history of cancer in the 3 years before inclusion into the study
- •Major surgery within 4 weeks before sunitinib initiation
- •Past history of symptomatic cerebral metastases, spinal cord compression or meningeal carcinomatosis. Patients with cerebral metastases discovered incidentally on imaging and who are asymptomatic are not excluded if these metastases have been treated (radiotherapy and/or surgery) with a period of at least 4 weeks between the end of treatment and inclusion into the study and no clinical or radiological signs of relapse, and corticosteroid dose is not exceeding 10mg/day of prednisone or equivalent. Subjects will be excluded if subjects have signs of grade ≥ 2 treatment-related complications.
- •Any of the following features within 6 months of the administration of Sunitinib: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.
- •Pulmonary embolism or deep vein thrombosis within 3 months of inclusion (unless it's stable, asymptomatic and treated with a low molecular weight heparin for at least 6 weeks before inclusion).
- •Any known acute or chronic disorder (such as severe chronic obstructive pulmonary disease) which in the opinion of the investigator could impact on the patient's capacity to receive the study treatment or make interpretation of toxicity or adverse events difficult.
- •Known HIV infection.
- •History of chronic active hepatitis including subjects who are carriers of the hepatitis B (HBV) or hepatitis C (HCV) virus.
- •Existence of uncontrolled infection.
- •Uncontrolled hypertension defined as a blood pressure of > 150 mmHg systolic or > 100 mmHg diastolic despite optimal anti-hypertensive therapy (blood pressure must be controlled at inclusion).
研究组 & 干预措施
Arm A 4/6
Active Comparator
Sunitinib 37.5 mg/day; regimen 4/6 (Marketing Authorisation Indication) 4 weeks "on " alternating with 2 weeks "off "
干预措施: Sunitinib (Drug)
Arm B 2/3
Experimental
Sunitinib 50 mg/day; regimen 2/3 (experimental arm) 2 weeks "on " alternating with 1 week "off "
干预措施: Sunitinib (Drug)
结局指标
主要结局
MDT (median duration of treatment)
时间窗: 12 mo
The primary objective of this study is to estimate the median duration of treatment in each treatment group (arm A vs arm B) calculated from sunitinib initiation.
次要结局
- PFS (progression-free survival)(12 months)
- duration of sunitinib post randomization(12 months)
- time to randomization(4 months)
- OS (overall survival)(30 months)
- ORR (objective response rate)(6 months)
- QOL (quality of life)(24 months)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)Metastatic Renal Cell CarcinomaNCT00570882Asan Medical Center76
已完成
2 期
Efficacy and Safety of Sunitinib in Metastatic Gastric CancerGastric AdenocarcinomaBarrett EsophagusNCT00411151Johannes Gutenberg University Mainz52
招募中
不适用
Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.Metastatic renal cell cancer - uitgezaaide nierkankerSunitinib rechallenge - herbehandeling met sunitinibSunitinib - SunitinibNL-OMON21668VU Medical Center45
已完成
2 期
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT00903175Novartis Pharmaceuticals471
终止
2 期
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)Liver CancerNCT00495625H. Lee Moffitt Cancer Center and Research Institute33